Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | P162S |
Impact List | missense |
Protein Effect | no effect - predicted |
Gene Variant Descriptions | BRAF P162S lies within the RBD domain of the Braf protein (UniProt.org). P162S has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Braf in culture (PMID: 29533785), and therefore, is predicted to have no effect on Braf protein function. |
Associated Drug Resistance | |
Category Variants Paths |
BRAF mutant BRAF P162S |
Transcript | NM_004333.6 |
gDNA | chr7:g.140834629G>A |
cDNA | c.484C>T |
Protein | p.P162S |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017012558.1 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
XM_017012559.2 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
NM_001374258.1 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
NM_001374244.1 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
NM_001354609.2 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
NM_004333.5 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
NM_001378468.1 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
XM_047420769.1 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
XM_047420767.1 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
NM_001354609.1 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
NM_001378471.1 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
XM_017012559.1 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
NM_004333 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
NM_001378474.1 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
XM_017012559 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
XM_005250045 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
NM_001378469.1 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
XM_047420768.1 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
NM_004333.6 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
XM_017012558 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
NM_001378467.1 | chr7:g.140834629G>A | c.484C>T | p.P162S | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|